AAM
AIMT

Alpine Associates Management’s Aimmune Therapeutics AIMT Stock Holding History

Alpine Associates Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,075,100
Closed -$71.5M – 54
2020
Q3 		$71.5M Buy
+2,075,100
New +$44.2M 3.76% 13

Alpine Associates Management's AIMT Position: Q4 2020 in Review

Alpine Associates Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 2,075,100 shares — an estimated $71.5M sold.

Alpine Associates Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $71.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Alpine Associates Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Alpine Associates Management sold 2,075,100 Aimmune Therapeutics shares in Q4 2020, an estimated $71.5M.
  • Alpine Associates Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Alpine Associates Management's Aimmune Therapeutics position peaked at $71.5M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Alpine Associates Management's 13F filing for Q4 2020, filed 10 Feb 2021.